Last reviewed · How we verify
SAFE group
At a glance
| Generic name | SAFE group |
|---|---|
| Also known as | simulated amniotic fluid like solution 20cc/kg/day enterally |
| Sponsor | Rania Ali El-Farrash |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Adaptation and RCT of Written Exposure Therapy for Adolescents (NA)
- A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults (PHASE1)
- The Trans-Led Care Study (NA)
- NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty (NA)
- A Study of Hospital-at-Home for People Receiving Tarlatamab (NA)
- Virtual Reality-Based Vestibular Rehabilitation in Vestibular Migraine (NA)
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment (PHASE3)
- Kentucky Women's Justice Community Overdose Innovation Network - Phase II (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAFE group CI brief — competitive landscape report
- SAFE group updates RSS · CI watch RSS
- Rania Ali El-Farrash portfolio CI